Type 1 diabetes therapy reshapes around disease modification and automation
Teplizumab disease modification, automated insulin delivery system maturity, and emerging beta-cell replacement programs are restructuring T1D management.
Type 1 diabetes has been an exogenous insulin category since 1922. Teplizumab delays clinical T1D onset in stage 2 disease and is now in active commercial use; automated insulin delivery systems (closed-loop pumps with continuous glucose monitoring) are the standard for patients with access; allogeneic and stem-cell-derived beta-cell replacement programs are reading out in pivotal data. The category is structurally evolving for the first time in a century.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.